Latest Regulatory Approval News

Johns Lyng Group has entered a binding scheme implementation deed with Pacific Equity Partners for a $1.1 billion acquisition at $4.00 per share, representing a significant premium and a 10.3x EV/EBITDA multiple. The transaction awaits shareholder and regulatory approvals, with major shareholder backing and a clear timetable set for late 2025.

Chariot Corporation Ltd is set to acquire a 66.7% interest in a substantial Nigerian lithium portfolio, marking a strategic entry into Africa’s burgeoning lithium sector with a US$10 million funding commitment.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Kinterra Capital GP Corp. II has increased its takeover offer for New World Resources Limited to A$0.062 per share, presenting shareholders with a superior all-cash proposal compared to rival Central Asia Metals Plc. The offer, backed by Kinterra’s 19.3% stake, aims for full ownership and potential delisting of NWR.

Emperor Energy has raised $3.7 million through a share placement to advance the Judith-2 appraisal well in Victoria’s Gippsland Basin, backed by independent resource validation and strategic infrastructure proximity.

Finbar Group has acquired the Palmyra development site from its JV partner, transforming it into a wholly-owned project valued at $88 million with settlement expected in early 2026.

Zenith Minerals has successfully raised A$3.5 million through a fully underwritten rights issue, positioning the company to fast-track exploration and resource growth at its key gold projects in Western Australia and Queensland.

Mithril Silver and Gold Limited has announced a C$10 million brokered private placement to fund expanded exploration at its Copalquin district project in Mexico. The raise includes an option for agents to increase the placement by 15%, underscoring strong investor interest.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Capricorn Metals has agreed to acquire the Claw Gold Project adjacent to its Mt Gibson operation, aiming to unlock new gold resources in Western Australia’s prolific Murchison region.